2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05031351 (ClinicalTrials.gov) | September 2021 | 5/8/2021 | NF-?B Inhibition in Amyotrophic Lateral Sclerosis | Nuclear Factor Kappa Beta Inhibition in Patients With Amyotrophic Lateral Sclerosis: A Phase II Randomized Placebo Controlled Trial | ALS | Drug: Withania somnifera;Drug: Placebo | Sunnybrook Health Sciences Centre | NULL | Not yet recruiting | 18 Years | N/A | All | 75 | Phase 2 | NULL |